Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer

Jun Araki; Isamu Okamoto; Ryuichiro Suto; Yasuko Ichikawa; Ji Ichiro Sasaki

doi:10.1016/j.lungcan.2004.10.012

Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer

Jun Araki, Isamu Okamoto, Ryuichiro Suto, Yasuko Ichikawa, Ji Ichiro Sasaki

Respiratory Medicine

Research output: Contribution to journal › Article › peer-review

40 Citations (Scopus)

Abstract

Gefitinib (Iressa, ZD1839) is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). There has been no report to date of the effect of gefitinib treatment in patients with small-cell lung cancer (SCLC). Here we report a case of metastatic SCLC that was successfully treated with gefitinib. This case is the first reported of objective clinical response after gefitinib treatment in a patient with SCLC. Our report suggests that treatment with gefitinib is a novel option for a subset of patients with SCLC.

Original language	English
Pages (from-to)	141-144
Number of pages	4
Journal	Lung Cancer
Volume	48
Issue number	1
DOIs	https://doi.org/10.1016/j.lungcan.2004.10.012
Publication status	Published - Apr 2005

All Science Journal Classification (ASJC) codes

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lungcan.2004.10.012

Cite this

@article{1e2ac4a328194c86ae8c27658efa3848,

title = "Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer",

abstract = "Gefitinib (Iressa, ZD1839) is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). There has been no report to date of the effect of gefitinib treatment in patients with small-cell lung cancer (SCLC). Here we report a case of metastatic SCLC that was successfully treated with gefitinib. This case is the first reported of objective clinical response after gefitinib treatment in a patient with SCLC. Our report suggests that treatment with gefitinib is a novel option for a subset of patients with SCLC.",

author = "Jun Araki and Isamu Okamoto and Ryuichiro Suto and Yasuko Ichikawa and Sasaki, {Ji Ichiro}",

year = "2005",

month = apr,

doi = "10.1016/j.lungcan.2004.10.012",

language = "English",

volume = "48",

pages = "141--144",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer

AU - Araki, Jun

AU - Okamoto, Isamu

AU - Suto, Ryuichiro

AU - Ichikawa, Yasuko

AU - Sasaki, Ji Ichiro

PY - 2005/4

Y1 - 2005/4

N2 - Gefitinib (Iressa, ZD1839) is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). There has been no report to date of the effect of gefitinib treatment in patients with small-cell lung cancer (SCLC). Here we report a case of metastatic SCLC that was successfully treated with gefitinib. This case is the first reported of objective clinical response after gefitinib treatment in a patient with SCLC. Our report suggests that treatment with gefitinib is a novel option for a subset of patients with SCLC.

AB - Gefitinib (Iressa, ZD1839) is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). There has been no report to date of the effect of gefitinib treatment in patients with small-cell lung cancer (SCLC). Here we report a case of metastatic SCLC that was successfully treated with gefitinib. This case is the first reported of objective clinical response after gefitinib treatment in a patient with SCLC. Our report suggests that treatment with gefitinib is a novel option for a subset of patients with SCLC.

UR - http://www.scopus.com/inward/record.url?scp=15044365905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15044365905&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2004.10.012

DO - 10.1016/j.lungcan.2004.10.012

M3 - Article

C2 - 15777982

AN - SCOPUS:15044365905

SN - 0169-5002

VL - 48

SP - 141

EP - 144

JO - Lung Cancer

JF - Lung Cancer

IS - 1

ER -

Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this